Overview Financials News + Filings Key Docs Charts Ownership Insiders
|
|
Minerva Neurosciences, Inc. (NERV)
|
Add to portfolio |
|
|
|
| Price: |
$2.42
| | Metrics |
| OS: |
5.57
|
M
| |
|
|
| Market cap: |
$13.5
|
M
| |
|
|
|
Net cash:
|
$36
|
M
| |
$6.46
|
per share
|
|
EV:
|
|
| | | |
| | | | | |
| TTM Valuation | | | |
|
EBITDA
|
|
| |
|
|
|
EBIT
|
|
| |
|
|
| EPS |
($5.49)
| |
|
|
|
|
| |
|
|
|
Recent News + Filings (All items)
|
Revenue Mix by Segment
|
Financial Summary (All financials)
| In millions, except per share items | Dec-31-22 | Dec-31-21 | Dec-31-20 | Dec-31-19 | Dec-31-18 | Dec-31-17 | Dec-31-16 | Dec-31-15 |
| Revenues | 0.0 | 0.0 | 41.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Revenue growth | | -100.0% | | | | | | |
| Cost of goods sold | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross profit | 0.0 | 0.0 | 41.2 | 0.0 | 0.0 | 0.0 | 0.0 | 0.0 |
| Gross margin | | | 100.0% | | | | | |
| Selling, general and administrative | 25.2 | 45.4 | | | | | | |
| Research and development | | | 22.0 | 58.1 | 34.9 | 30.3 | 20.4 | 18.5 |
| General and administrative | | | 17.3 | 17.7 | 16.8 | 10.9 | 9.8 | 7.6 |
| EBIT | -25.2 | 0.0 | 1.8 | -75.9 | -51.7 | -41.2 | -30.2 | -26.1 |
| EBIT margin | | | 4.5% | | | | | |
| Pre-tax income | -32.1 | -51.7 | 1.9 | -74.4 | -50.2 | -40.9 | -31.0 | -27.1 |
| Income taxes | 0.0 | -1.8 | 0.0 | -2.3 | 0.0 | -9.4 | 0.0 | 0.0 |
| Tax rate | 0.0% | 3.5% | 0.0% | 3.0% | 0.0% | 22.9% | 0.0% | 0.0% |
| Net income | -32.1 | -49.9 | 1.9 | -72.2 | -50.2 | -31.5 | -31.0 | -27.1 |
| Net margin | | | 4.7% | | | | | |
| |
| Diluted EPS | ($6.01) | ($9.35) | $0.05 | ($1.85) | ($1.29) | ($0.83) | ($0.99) | ($1.16) |
| Shares outstanding (diluted) | 5.3 | 5.3 | 40.9 | 39.0 | 38.8 | 37.9 | 31.5 | 23.4 |
| |
| EBIT is a non-GAAP figure that excludes all non-recurring expenses: restructuring costs, asset impairments, IPR&D writeoffs, and other unusual charges. |
|
|